Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
| ▸ | P4HTM | Q9NXG6 | 11/20 | 0.52 |
| ▸ | JAK2 | O60674 | 5/20 | 0.50 |
| ▸ | TYK2 | P29597 | 5/20 | 0.50 |
| ▸ | JAK1 | P23458 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5999675 | 0.82 | LCK (0.57) | LCKMAPK14JAK2TYK2JAK1 | |
| SCHEMBL5998110 | 0.79 | P4HTM (0.48) | P4HTM | |
| SCHEMBL5997660 | 0.78 | LCK (0.55) | LCKMAPK14JAK2TYK2 | |
| SCHEMBL5998293 | 0.75 | TYK2 (0.56) | LCKP4HTMTYK2RORC | |
| SCHEMBL2495621 | 0.74 | BTK (0.75) | LCKMAPK14JAK2 | |
| SCHEMBL2501233 | 0.74 | P4HTM (0.49) | P4HTM | |
| SCHEMBL5998031 | 0.72 | LCK (0.62) | LCKMAPK14JAK2TYK2CYP3A4 | |
| SCHEMBL5997968 | 0.72 | MAPK14 (0.74) | LCKMAPK14JAK2 | |
| SCHEMBL12190166 | 0.72 | CYP11B2 (0.63) | JAK2TYK2 | |
| SCHEMBL5997075 | 0.72 | LCK (0.73) | LCKMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863794-A2 | PYRIMIDINE COMPOUNDS AND METHODS OF USE | Targegen, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
| WO-2006101977-A2 | PYRIMIDINE COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | LCK 4/4885MAPK14 401/4885P4HTM 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.